Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells
- PMID: 8647071
- DOI: 10.1111/j.1432-1033.1996.00344.x
Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells
Abstract
Gaucher's disease is an inherited lysosomal storage disorder that is caused by a deficiency of glucocerebrosidase. The resulting accumulation of the substrate glucosylceramide in macrophages of liver, spleen, and bone marrow causes severe clinical symptoms. Gaucher's disease is treated by intravenous administration of a modified glucocerebrosidase (Alglucerase), which has exposed mannose residues to promote uptake by target macrophages. To evaluate the effectiveness of the targeting of Alglucerase, we studied the fate of the enzyme in the rat. Intravenously injected Alglucerase was rapidly cleared from the circulation (half-life 2.0 +/- 0.5 min). The liver was the main site of uptake, with 65.6 +/- 1.2% of the dose present at 10 min after injection. Smaller amounts ( < 3% of the dose) were taken up by spleen and bone marrow. Previous injection with mannan substantially increased the plasma half-life of the enzyme (14.8 +/- 3.2 min versus 1.7 +/- 0.3 min in solvent-preinjected controls) and uptake of the enzyme by liver, spleen and bone marrow was reduced by > 90%. These findings indicate that the enzyme is taken up by these organs via mannose-specific receptors. Subcellular fractionation of the liver indicated that the enzyme is internalized and transported to the lysosomes. By isolating various liver cell types after injection of the Alglucerase, it was found that endothelial cells are the main site of uptake of the enzyme: 60.8 +/- 3.4% of the total liver uptake. Parenchymal and Kupffer cells were responsible for 31.0 +/- 3.1% and 8.2 +/- 0.7% of the hepatic uptake, respectively. We conclude that Alglucerase is rapidly cleared from the circulation by mannose-specific receptors in liver, spleen, and bone marrow. However, less than 10% of the enzyme taken up by the liver is accounted for by Kupffer cells, the hepatic target cells for therapeutic intervention. It is suggested that alterations of the formulation of the therapeutic enzyme may lead to a higher uptake by Kupffer cells and other macrophages, and thus to a more (cost)effective therapy of Gaucher's disease.
Similar articles
-
A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease.Blood. 1999 May 1;93(9):2807-16. Blood. 1999. PMID: 10216074
-
Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease.Lancet. 1996 Dec 7;348(9041):1555-9. doi: 10.1016/S0140-6736(96)04451-0. Lancet. 1996. PMID: 8950883
-
Alglucerase. A review of its therapeutic use in Gaucher's disease.Drugs. 1992 Jul;44(1):72-93. doi: 10.2165/00003495-199244010-00007. Drugs. 1992. PMID: 1379912 Review.
-
A biochemical and immunocytochemical study on the targeting of alglucerase in murine liver.Histochem J. 1995 Aug;27(8):639-46. Histochem J. 1995. PMID: 8550385
-
Gaucher's disease: a review.Ann Pharmacother. 1996 Apr;30(4):381-8. doi: 10.1177/106002809603000411. Ann Pharmacother. 1996. PMID: 8729893 Review.
Cited by
-
Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.Orphanet J Rare Dis. 2014 Jun 30;9:95. doi: 10.1186/1750-1172-9-95. Orphanet J Rare Dis. 2014. PMID: 24980507 Free PMC article.
-
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.Genet Med. 2009 Feb;11(2):92-100. doi: 10.1097/GIM.0b013e31818e2c19. Genet Med. 2009. PMID: 19265748 Free PMC article.
-
Receptor-mediated and fluid-phase transcytosis of horseradish peroxidase across rat hepatocytes.J Biomed Biotechnol. 2010;2010:850320. doi: 10.1155/2010/850320. Epub 2010 Jan 27. J Biomed Biotechnol. 2010. PMID: 20168981 Free PMC article.
-
Gaucher disease: new developments in treatment and etiology.World J Gastroenterol. 2008 Jul 7;14(25):3968-73. doi: 10.3748/wjg.14.3968. World J Gastroenterol. 2008. PMID: 18609679 Free PMC article. Review.
-
Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition.Hum Mol Genet. 2018 Mar 1;27(5):811-822. doi: 10.1093/hmg/ddx442. Hum Mol Genet. 2018. PMID: 29301038 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources